-1%
AndroGel 1.62% Gel is indicated for testosterone replacement therapy in adult men with conditions associated with inadequate or absent endogenous testosterone production.
AndroGel 1.62% is used in the treatment of male hypogonadism, including:
Primary hypogonadism (congenital or acquired):
Testicular failure resulting from conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage caused by alcohol or heavy metals. These patients typically exhibit low serum testosterone levels with elevated gonadotropins (FSH and LH).
Hypogonadotropic hypogonadism (congenital or acquired):
Conditions resulting from gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic damage due to tumors, trauma, or radiation. These patients have low serum testosterone levels with normal or reduced gonadotropin concentrations.